Aprea Therapeutics (NASDAQ:APRE) shares are trading higher on Wednesday as the company announced additional preliminary data from its ongoing Phase 1 trial of APR-1051, a WEE1 kinase inhibitor.
Cancer Trial Data
The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer during the trial, with a 50% reduction in target lesion measurements. Additionally, CA-125 tumor biomarker levels dropped significantly, from 362 U/mL at baseline to 47 U/mL, indicating promising anti-tumor activity.
Enrollment in the 220 mg dose cohort continues, and Aprea plans to expand the study to include more patients with specific genetic alterations. The ongoing trial aims to evaluate the safety and efficacy of APR-1051, with further updates expected in the second quarter of 2026.
Analyst Consensus & Recent Actions
The stock carries a Buy Rating. Recent analyst moves include:
- Wedbush: Outperform (Lowers Target to $7.00) (Feb. 10)
- HC Wainwright & Co.: Buy (Lowers Target to $4.00) (Jan. 29)
APRE Price Action: Aprea Therapeutics shares were up 16.62% at $0.70 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments